Journal
PLOS ONE
Volume 11, Issue 1, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0147211
Keywords
-
Categories
Funding
- European Union (Marie Curie) [IRG270459]
- Instituto de Salud Carlos III y los Fondos Feder Europeos [PI13/125]
- Spanish Ministry of Science and Innovation [RYC-2009-05571]
- L'OREAL-Unesco Foundation
- Department of Health of the Government of Navarra
- Basque Foundation for Health Research (BIOEF) [BIO13/CI/005]
- Caja Navarra Foundation
- Credit Andorra Foundation
- University of Navarra
- Spanish Ministry of Education and Science [BIO2011-30299-C02-01]
- VCN bioscience
Ask authors/readers for more resources
Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro. In vivo, in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available